These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38293014)

  • 21. LIPAD (LRRK2/Luebeck International Parkinson's Disease) Study Protocol: Deep Phenotyping of an International Genetic Cohort.
    Usnich T; Vollstedt EJ; Schell N; Skrahina V; Bogdanovic X; Gaber H; Förster TM; Heuer A; Koleva-Alazeh N; Csoti I; Basak AN; Ertan S; Genc G; Bauer P; Lohmann K; Grünewald A; Schymanski EL; Trinh J; Schaake S; Berg D; Gruber D; Isaacson SH; Kühn AA; Mollenhauer B; Pedrosa DJ; Reetz K; Sammler EM; Valente EM; Valzania F; Volkmann J; Zittel S; Brüggemann N; Kasten M; Rolfs A; Klein C;
    Front Neurol; 2021; 12():710572. PubMed ID: 34475849
    [No Abstract]   [Full Text] [Related]  

  • 22. The role of tyrosine hydroxylase-dopamine pathway in Parkinson's disease pathogenesis.
    Zhou ZD; Saw WT; Ho PGH; Zhang ZW; Zeng L; Chang YY; Sun AXY; Ma DR; Wang HY; Zhou L; Lim KL; Tan EK
    Cell Mol Life Sci; 2022 Nov; 79(12):599. PubMed ID: 36409355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Back to the future: new target-validated Rab antibodies for evaluating LRRK2 signalling in cell biology and Parkinson's disease.
    Eyers PA
    Biochem J; 2018 Jan; 475(1):185-189. PubMed ID: 29305429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study.
    Quadri M; Mandemakers W; Grochowska MM; Masius R; Geut H; Fabrizio E; Breedveld GJ; Kuipers D; Minneboo M; Vergouw LJM; Carreras Mascaro A; Yonova-Doing E; Simons E; Zhao T; Di Fonzo AB; Chang HC; Parchi P; Melis M; Correia Guedes L; Criscuolo C; Thomas A; Brouwer RWW; Heijsman D; Ingrassia AMT; Calandra Buonaura G; Rood JP; Capellari S; Rozemuller AJ; Sarchioto M; Fen Chien H; Vanacore N; Olgiati S; Wu-Chou YH; Yeh TH; Boon AJW; Hoogers SE; Ghazvini M; IJpma AS; van IJcken WFJ; Onofrj M; Barone P; Nicholl DJ; Puschmann A; De Mari M; Kievit AJ; Barbosa E; De Michele G; Majoor-Krakauer D; van Swieten JC; de Jong FJ; Ferreira JJ; Cossu G; Lu CS; Meco G; Cortelli P; van de Berg WDJ; Bonifati V;
    Lancet Neurol; 2018 Jul; 17(7):597-608. PubMed ID: 29887161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autosomal dominant Parkinson's disease: Incidence of mutations in LRRK2, SNCA, VPS35 and GBA genes in Brazil.
    Abreu GM; Valença DC; Campos M; da Silva CP; Pereira JS; Araujo Leite MA; Rosso AL; Nicaretta DH; Vasconcellos LF; da Silva DJ; Della Coletta MV; Dos Santos JM; Gonçalves AP; Santos-Rebouças CB; Pimentel MM
    Neurosci Lett; 2016 Dec; 635():67-70. PubMed ID: 27777137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetics of Parkinson's Disease: From Causes to Treatment.
    Westenberger A; Brüggemann N; Klein C
    Cold Spring Harb Perspect Med; 2024 Aug; ():. PubMed ID: 39134389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
    Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
    Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of genetics in Parkinson's disease: a large cohort study in Chinese mainland population.
    Zhao Y; Qin L; Pan H; Liu Z; Jiang L; He Y; Zeng Q; Zhou X; Zhou X; Zhou Y; Fang Z; Wang Z; Xiang Y; Yang H; Wang Y; Zhang K; Zhang R; He R; Zhou X; Zhou Z; Yang N; Liang D; Chen J; Zhang X; Zhou Y; Liu H; Deng P; Xu K; Xu K; Zhou C; Zhong J; Xu Q; Sun Q; Li B; Zhao G; Wang T; Chen L; Shang H; Liu W; Chan P; Xue Z; Wang Q; Guo L; Wang X; Xu C; Zhang Z; Chen T; Lei L; Zhang H; Wang C; Tan J; Yan X; Shen L; Jiang H; Zhang Z; Hu Z; Xia K; Yue Z; Li J; Guo J; Tang B
    Brain; 2020 Jul; 143(7):2220-2234. PubMed ID: 32613234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rab GTPases: The Key Players in the Molecular Pathway of Parkinson's Disease.
    Shi MM; Shi CH; Xu YM
    Front Cell Neurosci; 2017; 11():81. PubMed ID: 28400718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data.
    Khan NL; Jain S; Lynch JM; Pavese N; Abou-Sleiman P; Holton JL; Healy DG; Gilks WP; Sweeney MG; Ganguly M; Gibbons V; Gandhi S; Vaughan J; Eunson LH; Katzenschlager R; Gayton J; Lennox G; Revesz T; Nicholl D; Bhatia KP; Quinn N; Brooks D; Lees AJ; Davis MB; Piccini P; Singleton AB; Wood NW
    Brain; 2005 Dec; 128(Pt 12):2786-96. PubMed ID: 16272164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of LRRK2 and SNCA in autosomal dominant Parkinson's disease in Turkey.
    Kessler C; Atasu B; Hanagasi H; Simón-Sánchez J; Hauser AK; Pak M; Bilgic B; Erginel-Unaltuna N; Gurvit H; Gasser T; Lohmann E
    Parkinsonism Relat Disord; 2018 Mar; 48():34-39. PubMed ID: 29248340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
    Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
    Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
    Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.
    Liu SY; Wile DJ; Fu JF; Valerio J; Shahinfard E; McCormick S; Mabrouk R; Vafai N; McKenzie J; Neilson N; Perez-Soriano A; Arena JE; Cherkasova M; Chan P; Zhang J; Zabetian CP; Aasly JO; Wszolek ZK; McKeown MJ; Adam MJ; Ruth TJ; Schulzer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2018 Apr; 17(4):309-316. PubMed ID: 29456161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study.
    Funayama M; Ohe K; Amo T; Furuya N; Yamaguchi J; Saiki S; Li Y; Ogaki K; Ando M; Yoshino H; Tomiyama H; Nishioka K; Hasegawa K; Saiki H; Satake W; Mogushi K; Sasaki R; Kokubo Y; Kuzuhara S; Toda T; Mizuno Y; Uchiyama Y; Ohno K; Hattori N
    Lancet Neurol; 2015 Mar; 14(3):274-82. PubMed ID: 25662902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson's Disease?
    O'Hara DM; Pawar G; Kalia SK; Kalia LV
    Front Neurosci; 2020; 14():577. PubMed ID: 32625052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PINK1-dependent phosphorylation of Serine111 within the SF3 motif of Rab GTPases impairs effector interactions and LRRK2-mediated phosphorylation at Threonine72.
    Vieweg S; Mulholland K; Bräuning B; Kachariya N; Lai YC; Toth R; Singh PK; Volpi I; Sattler M; Groll M; Itzen A; Muqit MMK
    Biochem J; 2020 May; 477(9):1651-1668. PubMed ID: 32227113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Update on the Interplay between LRRK2, Rab GTPases and Parkinson's Disease.
    Komori T; Kuwahara T
    Biomolecules; 2023 Nov; 13(11):. PubMed ID: 38002327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical molecular genetics for PARK8 (LRRK2)].
    Tomiyama H; Hatano T; Hattori N
    Brain Nerve; 2007 Aug; 59(8):839-50. PubMed ID: 17713120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.